Avaleht › T-raku lümfoom › California
T-raku lümfoom kliinilised uuringud osariigis California
13 uuringut haiguse T-raku lümfoom jaoks otsivad osalejaid osariigis California.
Linnad osariigis California
Ametlik uuringutekst (inglise keeles)
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Cedars-Sinai Medical Center, Los Angeles
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 2. okt 2026 · NCT04803201Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- City of Hope National Medical Center, Duarte
- University of California, Irvine, Irvine
- University of California San Francisco, San Francisco
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT06561048BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
- City of Hope National Medical Center, Duarte
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 18. sept 2026 · NCT04752826Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank
- City of Hope Comprehensive Cancer Center, Duarte
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- ja veel 4
VärbamineFaas 3
Vanused 18–75 · Kõik sood · Uuendatud 14. sept 2026 · NCT06724237A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
- City of Hope Comprehensive Cancer Cente, Duarte
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 9. sept 2026 · NCT06854653Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Rady Children's Hospital, San Diego
VärbamineFaas 2
Vanused 1–18 · Kõik sood · Uuendatud 10. aug 2026 · NCT06390319Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
- City of Hope Medical Center, Duarte
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 5. aug 2026 · NCT07293403Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
- City of Hope Medical Center, Duarte
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 31. juuli 2026 · NCT03011814Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
- City of Hope Medical Center, Duarte
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 5. juuni 2026 · NCT07278856A Registry for People With T-cell Lymphoma
- City of Hope Cancer Center (Data collection only), Duarte
- UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only), San Diego
- University of California San Francisco (Data collection only), San Francisco
- ja veel 1
VärbamineVaatlusuuring
Kõik vanused · Kõik sood · Uuendatud 20. mai 2026 · NCT05978141MB-105 in Patients With CD5 Positive T-cell Lymphoma
- University of San Diego (UCSD)-Moores Cancer Center, San Diego
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 3. okt 2025 · NCT06534060Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- City of Hope Medical Foundation, Duarte
- University of Southern California, Los Angeles
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2025 · NCT04234048Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital Los Angeles, Los Angeles
- Children's Hospital Orange County, Orange
- UCSF School of Medicine, San Francisco
VärbamineFaas 1
Vanused 1–21 · Kõik sood · Uuendatud 6. dets 2024 · NCT05476770Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.